Post archive for ‘Company Reports’
Antares Is Initated As A Buy Based On Broad, Promising Pipeline (AIS, $2.59)
Investment Opinion I am recommending purchase of Antares (AIS) at the current level of $2.59. My 2015 price target is $6.70. Antares has a broad array of products based on its self-injection and gel formulation drug delivery technologies. Its partners are currently marketing four Antares products and there are eight more in development. I estimate […]
Initiating Coverage of MAP Pharmaceuticals with A Buy Based On Potential for Levadex (MAPP, $13.35)
Investment Opinion Map Pharmaceuticals is poised to introduce its first commercial product, Levadex (inhaled dihydroergotamine) that is indicated for treating acute migraine attacks. I consider Levadex to be a very important new drug with significant commercial potential. The PDUFA date is March 26, 2012. Triptans (Imitrex, Axert, Frova, Maxalt, Relpax, Treximet and Zomig) are […]
Libi-Gel Phase III Trial Results Should Be Released Shortly (AIS, $2.73)
Investment Overview One of the eleven products that Antares has in late stage development is Libi-Gel for treating female sexual dysfunction based on testosterone replacement. This product is licensed to BioSante for the US and certain foreign markets while Antares retains rights for Europe. The phase III trials for Libi-Gel are expected to be […]
Collaboration with Teva on Self-Injected Drugs Is the Major Driver of the Investment Thesis (AIS, $2.68)
Investment Thesis In my initial report on Antares, I recommended purchase based importantly on the potential for its self-injection technology. One of the mega-trends in the world pharmaceutical industry is the increasing importance of injectable drugs. Antares cites projections that injectable drugs (largely biologic agents) will account for 50% of the top selling drugs in […]
Approval of Anturol Is Significant Positive (AIS, $2.68)
Anturol Approval is A Major Positive Recently, I wrote a note about Anturol discussing its therapeutic profile and the commercialization agreement with Watson. I also wrote an earlier report in which I recommended purchase of Antares. I thought that Anturol had a very high probability for approval, but the FDA has been so risk adverse […]
Anturol’s December 8th PDUFA Date Is Looming (AIS, $2.77)
Introduction I recently began coverage of Antares with a buy. The basis of my recommendation was the exceptional pipeline of drugs that the company is working on. In my initial report, I could not go into great detail on each of these products so that I plan a series of reports that focus on just […]
How Big is the Chronic Refractory Gout Market Addressed by Krysrexxa? (SVNT, $2.28)
Introduction The size of the chronic refractory gout market that Krystexxa targets have been a concern to investors and some believe that the slow takeoff of Krystexxa signals that this is a very small patient population. Because there has been no effective drug therapy, there is almost no experience to draw on to help estimate […]
Initiating Coverage of Savient Pharmaceuticals with a Buy: Initial Launch of Krystexxa Has Been Disappointing but I Believe That This is a Breakrhrough Drug with Great Potential (SVNT, $2.35)
Investment Opinion I am recommending purchase of Savient Pharmaceuticals at the current price of $2.35. My recommendation is based on the estimate that Krystexxa sales could reach $209 million in 2015 and my valuation methodology suggests that the stock could sell at $6.40 to $8.50 in 2015. The initial launch of Krystexxa has been slow […]
Are Investors So Pessimistic On Provenge That They Are Ignoring Some Positive Trends (DNDN, $8.78)
Key Investment Issues Investment sentiment on Dendreon has deteriorated so much that investors seem to be only focusing on what has gone wrong and what can go wrong. I think that this pervasive state of gloominess is causing people to ignore some encouraging signs. Reimbursement has become predictable for physicians and most are receiving payment […]
Achillion Could Be On Big Pharma’s Acquisition List (ACHN, $6.00)
Gilead (GILD) is certainly paying up for Pharmasset with its offer to buy the company at $137 per share ($11 billion), an 89% premium to last Friday’s close. Gilead will be paying for the acquisition with cash on hand and debt. Relative to alternatives such as investing money in short term debt instruments or doing […]